<?xml version="1.0" encoding="UTF-8"?>
<p id="Par70">The TCN-032 antibody passed phase I of clinical trials. Volunteers were given a single dose of TCN-032 intravenously (1, 3, 10, 20, or 40â€‰mg/kg of body weight), and no severe events related to the study drug were observed. A phase II clinical trial showed that non-neutralizing antibody TCN-032 has a therapeutic effect, as parenteral administration provided immediate immunity and therapeutic benefit in influenza A infection [
 <xref ref-type="bibr" rid="CR99">99</xref>].
</p>
